MBX Biosciences (MBX) EBITDA (2023 - 2026)

MBX Biosciences has reported EBITDA for 4 years, with the latest figure at -$27.3 million in Q1 2026.

• Quarterly EBITDA fell 2.77% year-over-year to -$27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.8 million (down 21.35% YoY) and the FY2025 annual result came in at -$98.1 million, down 43.79% from the prior year.
• EBITDA declined to -$27.3 million in Q1 2026 per MBX's latest filing, from -$25.8 million in the prior quarter.
• Over five years, EBITDA peaked at -$10.0 million in Q4 2023 and troughed at -$27.3 million in Q1 2026.
• A 4-year average of -$19.5 million and a median of -$19.6 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2025 and 2026: EBITDA tumbled 99.26% in 2025, then declined 2.77% in 2026.
• Over 4 years, EBITDA stood at -$10.0 million in 2023, then plunged by 86.27% to -$18.6 million in 2024, then plunged by 38.61% to -$25.8 million in 2025, then declined by 5.7% to -$27.3 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$27.3 million, -$25.8 million, and -$23.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.